GlaxoSmithKline PLC (LSE:GSK) - Share price - Overview

Not a customer yet?

Buy shares from £4.95 with our easy-to-use SIPPs, ISAs and Dealing accounts

Find out more

Stock Report

GlaxoSmithKline PLC GSK

Last Price
GBX1,563.80

Day Change
2.80|0.18%

As of 18/07/2018
18:38:57 BST | GBX
Minimum 15 Minutes Delay.

Last Close1,561.00p
Day Range1,563.00 - 1,591.20
Mkt Cap77.42Bil
52-Wk Range1,236.40 - 1,632.00
Yield %5.12
ISINGB0009252882
Volume9,146,923
P/E28.73
P/S0.03
P/CF0.11

Share Price

Total Returns 17/07/2018

 Chg (%)  
More ...
GlaxoSmithKline PLC0.32 
FTSE 100 TR GBP0.03
 
Financials
201520162017
More ...
Income Statement
Turnover23,923.0027,889.0030,186.00
Operating Profit2,628.006,026.006,061.00
Net Profit8,372.001,062.002,169.00
Reported EPS172.3018.6031.00
Balance Sheet
Current Assets16,541.0016,496.0015,794.00
Non Current Assets36,859.0042,370.0040,474.00
Total Assets53,446.0059,081.0056,381.00
Current Liabilities13,417.0019,001.0026,569.00
Total Liabilities44,568.0054,118.0052,892.00
Total Equity8,878.004,963.003,489.00
Cash Flow
Operating Cash Flow4,631.008,106.008,258.00
Net Change in Cash1,503.00-1,164.00-905.00

Regulatory News

Director Dealings
TradedActionNotifierPriceAmountValue
More ...
12/07/2018PurchaseMr. Simon Dingemans1,576.602493,926.00
12/07/2018PurchaseMr. Simon Dingemans1,576.601872,948.00
12/07/2018PurchaseMr. Simon Dingemans1,576.605108,041.00
12/07/2018PurchaseMr. Simon Dingemans1,576.602493,926.00

Company Profile

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Sector

Drug Manufacturers - Major

Index

FTSE 100 ,FTSE 350 ,FTSE All Share ,FTSE Eurotop 100 ,FTSE Eurotop 300

Next Event 25/07/2018

Half-Yearly Results
Ratios
Comp
More ...
PER (E)73.55
Div Yld (E)5.23
PEG (E)4.98
ROCE14.24
Op Mrgn0.20
EPS Grwth-0.27
Dividends
PreviousLatest
More ...
Record Date10/11/1723/02/18
Ex-Div09/11/1722/02/18
Paid11/01/1812/04/18
Amnt19.0023.00
Directors
More ...
Non-Executive DirectorMs. Lynn Laverty Elsenhans
Executive Director, Chief Scientific OfficerDr. Hal V. Barron,M.D.,F.A.C.C.
Non-Executive DirectorMs. Judy C. Lewent
Non-Executive DirectorDr. Laurie H. Glimcher,M.D.
Non-Executive DirectorMr. Manvinder Singh Banga
Non-Executive Director, ChairmanSir Philip Roy Hampton KB
Non-Executive DirectorMr. Urs Rohner
Non-Executive DirectorDr Vivienne Cox CBE
Non-Executive DirectorProf Sir Roy Anderson
Non-Executive DirectorDr. Jesse Goodman
Executive Director, Chief Financial OfficerMr. Simon Dingemans
Executive DirectorPatrick Vallance
Executive Director, Chief Executive OfficerEmma Walmsley
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2018 Morningstar. All rights reserved.